Is ceftriaxone (Ceftriaxone) contraindicated in patients with myasthenia gravis?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: December 14, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Ceftriaxone is NOT Contraindicated in Myasthenia Gravis

Ceftriaxone and other cephalosporins are safe to use in patients with myasthenia gravis, as they are not listed among medications that exacerbate this condition in current clinical guidelines. 1

Evidence Supporting Safety

Beta-lactam antibiotics, including cephalosporins like ceftriaxone, are generally considered safe options for treating infections in myasthenia gravis patients. 1 Ceftriaxone is recommended for various infections, including infective endocarditis, and is not contraindicated in patients with neurological conditions. 1

There is even a case report of a patient with myasthenia gravis who was successfully treated with ceftriaxone for neuroborreliosis, with the antibiotic being well-tolerated despite the underlying myasthenic condition. 2

Antibiotics That ARE Problematic in Myasthenia Gravis

While ceftriaxone is safe, certain other antibiotic classes should be avoided:

  • Fluoroquinolones should be avoided as they may trigger or exacerbate myasthenic symptoms. 1, 3
  • Aminoglycosides (streptomycin, amikacin, kanamycin) can precipitate or worsen myasthenic weakness. 3
  • Macrolide antibiotics are associated with myasthenic exacerbations. 3, 4

Notably, even penicillins (amoxicillin), traditionally considered safe, have been reported to cause acute worsening of myasthenia gravis symptoms in some patients, with exacerbations occurring within days of administration. 5

Clinical Advantages of Ceftriaxone

For serious infections requiring parenteral therapy in myasthenia gravis patients, ceftriaxone offers the advantage of once-daily dosing, which may be beneficial for outpatient management. 1

Key Clinical Caveat

When any new medication is introduced in a patient with myasthenia gravis, close monitoring for possible worsening of muscle weakness is essential, particularly in symptomatic patients with generalized disease who are especially vulnerable to drug-induced exacerbations. 6 However, this general precaution does not make ceftriaxone contraindicated—it simply reflects good clinical practice for this patient population.

References

Guideline

Safety of Ceftriaxone in Myasthenia Gravis Patients

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Guideline

Myasthenia Gravis: An Autoimmune Neuromuscular Junction Disorder

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Research

Exacerbation of myasthenia gravis after amoxicillin therapy: a case series.

Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology, 2020

Research

[Drugs that may trigger or exacerbate myasthenia gravis].

Tidsskrift for den Norske laegeforening : tidsskrift for praktisk medicin, ny raekke, 2013

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.